Form 4: Apellis Pharmaceuticals Chief Scientific Officer Sells Shares to Cover Tax Obligations

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 826 shares of common stock to cover tax withholding obligations related to released Restricted Stock Units.

Summary

• Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, sold 826 shares of the company's common stock on January 29, 2025.
• The sale was executed at a price of $29.5236 per share.
• This transaction was conducted to cover tax withholding obligations arising from the release of Restricted Stock Units on January 28, 2025.
• Following the transaction, Deschatelets directly owns 1,147,716 shares of Apellis Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment regarding the company's performance or outlook.

Industry Context

This is a routine transaction for company executives to manage their tax obligations related to stock-based compensation. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Similar transactions are regularly reported by executives at companies like Regeneron, Vertex, and Biogen when their stock options or restricted stock units vest.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes.

Key Dates

Keywords

Apellis Pharmaceuticals, insider trading, stock sale, Pascal Deschatelets, tax withholding, restricted stock units, APLS